APRE
Aprea Therapeutics, Inc.0.9110
-0.0141-1.52%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
5.75MP/E (TTM)
-Basic EPS (TTM)
-2.12Dividend Yield
0%Recent Filings
8-K
8-K
8-K
Nasdaq bid price deficiency
Aprea Therapeutics received a Nasdaq deficiency notice on January 23, 2026, for its common stock's closing bid price lingering below $1.00 over 30 business days, breaching Listing Rule 5550(a)(2). Trading continues uninterrupted under 'APRE' with 180 days until July 22 to hit $1.00 for 10 straight days. Reverse stock split looms as an option. No compliance guaranteed.
8-K
Updated pipeline presentation
Aprea Therapeutics updated its corporate presentation on January 9, 2026, highlighting Phase 1 progress for WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119. Early data show single-agent stable disease with tumor shrinkage up to 15% in heavily pretreated patients at doses from 70mg. Cash stands at ~$13.7M, funding into Q1 2027. Dose escalation advances.
8-K
Aprea raises $3.1M privately
Aprea Therapeutics signed a securities purchase agreement on December 8, 2025, for a $3.1M private placement of 2.623M shares (or pre-funded warrants) and common warrants exercisable at $1.04 for five years, closing December 10. Insiders and accredited investors joined via Maxim Group, with resale registration due within 20 days. Cash extends runway to Q1 2027. No dilutive resets.
ALLR
Allarity Therapeutics, Inc.
1.07+0.01
APLM
Apollomics Inc.
17.02+0.92
APLT
Applied Therapeutics, Inc.
0.12+0.00
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
BPTH
Bio-Path Holdings, Inc.
0.08+0.00
GNPX
Genprex, Inc.
2.43-0.15
LPTX
Leap Therapeutics, Inc.
2.05+1.61
MNPR
Monopar Therapeutics Inc.
71.47-3.65
PRLD
Prelude Therapeutics Incorporat
1.99+0.05
RPTX
Repare Therapeutics Inc.
2.23+0.03